Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), today announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Dr. Kramer brings more than 20 years of neuroscience-focused medical affairs leadership, having held senior roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. His expertise is expected to support Helus in advancing its pipeline of NSAs and strengthening engagement with clinical and scientific stakeholders.
The appointment comes as Helus Pharma progresses its lead candidate, HLP003, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address the large unmet need in MDD. Additionally, the company is developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs aimed at promoting neuroplasticity through serotonin pathway activation.
Dr. Kramer's background includes extensive experience in medical affairs strategy, clinical development, and stakeholder engagement. At Karuna Therapeutics, he contributed to the development of KarXT, a treatment for schizophrenia. His leadership at AbbVie and Bristol Myers Squibb further honed his skills in neuroscience therapeutic areas. Helus Pharma expects Kramer to play a key role in driving the company's medical affairs initiatives as it prepares for potential commercialization.
Helus Pharma, the commercial operating name of Cybin Inc., operates in Canada, the United States, the United Kingdom, and Ireland. The company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, aiming to provide durable improvements in mental health for patients suffering from depression, anxiety, and other conditions. For more information about Helus Pharma and its pipeline, visit www.helus.com.
The latest news and updates regarding HELP are available in the company's newsroom at https://ibn.fm/HELP. The full press release on the appointment can be viewed at https://ibn.fm/FdEXH.
